Attached files
file | filename |
---|---|
EX-3.2 - EX-3.2 - Foghorn Therapeutics Inc. | d71549dex32.htm |
EX-3.1 - EX-3.1 - Foghorn Therapeutics Inc. | d71549dex31.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 27, 2020
FOGHORN THERAPEUTICS INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-39634 | 47-5271393 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) | ||
500 Technology Square, Ste 700 Cambridge, MA |
02139 | |||
(Address of principal executive offices) | (Zip Code) |
(Registrants telephone number, including area code): 617-586-3100
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Common Stock, $0.0001 par value per share | FHTX | The Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On October 27, 2020, in connection with the consummation of Foghorn Therapeutics Inc.s (the Company) initial public offering of its common stock (the IPO), the Company filed a third amended and restated certificate of incorporation (the Restated Certificate) with the Secretary of State of the State of Delaware, which became effective upon filing. The Companys board of directors and stockholders previously approved the Restated Certificate to be filed in connection with the consummation of the IPO. The Restated Certificate amends and restates the Companys certificate of incorporation in its entirety to, among other things, (i) authorize 175 million shares of common stock, (ii) eliminate all references to previously-existing series of preferred stock, (iii) authorize 25 million shares of undesignated preferred stock that may be issued from time to time with the approval of the Companys board of directors in one or more series, and (iv) eliminate the ability of the Companys stockholders to take action by written consent in lieu of a meeting.
The foregoing description of the Restated Certificate is qualified by reference to the Restated Certificate, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.
Also on October 27, 2020, in connection with the consummation of the IPO, the amended and restated bylaws of the Company (the Amended and Restated Bylaws), previously approved by the Companys board of directors and stockholders to become effective immediately upon the consummation of the IPO, became effective. The Amended and Restated Bylaws amend and restate the Companys bylaws in their entirety to, among other things, (i) establish procedures relating to the presentation of stockholder proposals at stockholder meetings, (ii) establish procedures relating to the nomination of directors, (iii) modify the indemnification provisions for the Companys directors and officers, and (iv) conform to the amended provisions of the Restated Certificate.
The foregoing description of the Amended and Restated Bylaws is qualified by reference to the Amended and Restated Bylaws, a copy of which is attached hereto as Exhibit 3.2 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
Description | |
3.1 | Third Amended and Restated Certificate of Incorporation | |
3.2 | Amended and Restated Bylaws |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
FOGHORN THERAPEUTICS INC. | ||
By: | /s/ Allan Reine | |
Allan Reine, M.D. | ||
Chief Financial Officer |
Date: October 27, 2020